Interleukin-35 Expression in Non-Small Cell Lung Cancer is Associated with Tumor Progression

Mingfei Sun; Xianjie Zheng; Qingjiang Meng; Yanjun Dong; Guoyu Zhang; Dexin Rao; Xiaokang An; Zhongxin Yang; Lihong Pan; Shuanglin Zhang

doi:10.1159/000495706

Cellular Physiology and Biochemistry

Retracted Paper

Interleukin-35 Expression in Non-Small Cell Lung Cancer is Associated with Tumor Progression

Sun M. · Zheng X. · Meng Q. · Dong Y. · Zhang G. · Rao D. · An X. · Yang Z. · Pan L. · Zhang S.

Author affiliations

Department of Cardiovascular Thoracic Surgery, The First Affiliated Hospital of Henan University, Kaifeng City, China

Corresponding Author

Shuanglin Zhang

Dept. of Cardiovascular Thoracic Surgery, The 1^st Affiliated Hospital of Henan Univ.

357 Westgate Street, Kaifeng City, Henan Province, 475001 (China)

E-Mail zhangjianliqd@163.com

Key Words: Il-35Non-small Cell Lung CancerNSCLCInterleukin-35

References

Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, Stein KD, Alteri R, Jemal A: Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin 2016; 66: 271-289.

Siegel RL, Miller KD, Jemal A: Cancer statistics, 2016. CA Cancer J Clin 2016; 66: 7-30.

Torre LA, Sauer AM, Chen MS, Jr., Kagawa-Singer M, Jemal A, Siegel RL: Cancer statistics for Asian Americans, Native Hawaiians, and Pacific Islanders, 2016: Converging incidence in males and females. Cancer J Clin 2016; 66: 182-202.

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.

Dougan M, Li D, Neuberg D, Mihm M, Googe P, Wong KK, Dranoff G: A dual role for the immune response in a mouse model of inflammation-associated lung cancer. J Clin Invest 2011; 121: 2436-2446.

Zhong Z, Sanchez-Lopez E, Karin M: Autophagy, Inflammation, and Immunity: A Troika Governing Cancer and Its Treatment. Cell 2016; 166: 288-298.

Collison LW, Workman CJ, Kuo TT, Boyd K, Wang Y, Vignali KM, Cross R, Sehy D, Blumberg RS, Vignali DA: The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 2007; 450: 566-569.

Chaturvedi V, Collison LW, Guy CS, Workman CJ, Vignali DA: Cutting edge: Human regulatory T cells require IL-35 to mediate suppression and infectious tolerance. J Immunol 2011; 186: 6661-6666.

Nishino R, Takano A, Oshita H, Ishikawa N, Akiyama H, Ito H, Nakayama H, Miyagi Y, Tsuchiya E, Kohno N, Nakamura Y, Daigo Y: Identification of Epstein-Barr virus-induced gene 3 as a novel serum and tissue biomarker and a therapeutic target for lung cancer. Clin Cancer Res 2011; 17: 6272-6286.

Nicholl MB, Ledgewood CL, Chen X, Bai Q, Qin C, Cook KM, Herrick EJ, Diaz-Arias A, Moore BJ, Fang Y: IL-35 promotes pancreas cancer growth through enhancement of proliferation and inhibition of apoptosis: evidence for a role as an autocrine growth factor. Cytokine 2014; 70: 126-133.

Zhang Y, Sun H, Wu H, Tan Q, Xiang K: Interleukin 35 is an independent prognostic factor and a therapeutic target for nasopharyngeal carcinoma. Contemp Oncol (Pozn) 2015; 19: 120-124.

Fan YG, Zhai JM, Wang W, Feng B, Yao GL, An YH, Zeng C: IL-35 over-expression is associated with genesis of gastric cancer. Asian Pac J Cancer Prev 2015; 16: 2845-2849.

Fu YP, Yi Y, Cai XY, Sun J, Ni XC, He HW, Wang JX, Lu ZF, Huang JL, Cao Y, Zhou J, Fan J, Qiu SJ: Overexpression of interleukin-35 associates with hepatocellular carcinoma aggressiveness and recurrence after curative resection. Br J Cancer 2016; 114: 767-776.

Long J, Guo H, Cui S, Zhang H, Liu X, Li D, Han Z, Xi L, Kou W, Xu J, Li TS, Ding Y: IL-35 expression in hepatocellular carcinoma cells is associated with tumor progression. Oncotarget 2016; 7: 45678-45686.

Qiu X, Wang X, Song Y, Chen L: Plasma Level of Interleukin-35 as an Independent Prognostic Indicator in Hepatocellular Carcinoma. Dig Dis Sci 2016; 61: 3513-3521.

Chen G, Liang Y, Guan X, Chen H, Liu Q, Lin B, Chen C, Huang M, Chen J, Wu W, Liang Y, Zhou K, Zeng J: Circulating low IL-23: IL-35 cytokine ratio promotes progression associated with poor prognosisin breast cancer. Am J Transl Res 2016; 8: 2255-2264.

Zhao Z, Chen X, Hao S, Jia R, Wang N, Chen S, Li M, Wang C, Mao H: Increased interleukin-35 expression in tumor-infiltrating lymphocytes correlates with poor prognosis in patients with breast cancer. Cytokine 2017; 89: 76-81.

Jin L, Xu X, Ye B, Pan M, Shi Z, Hu Y: Elevated serum interleukin-35 levels correlate with poor prognosis in patients with clear cell renal cell carcinoma. Int J Clin Exp Med 2015; 8: 18861-18866.

Zeng JC, Zhang Z, Li TY, Liang YF, Wang HM, Bao JJ, Zhang JA, Wang WD, Xiang WY, Kong B, Wang ZY, Wu BH, Chen XD, He L, Zhang S, Wang CY, Xu JF: Assessing the role of IL-35 in colorectal cancer progression and prognosis. Int J Clin Exp Pathol 2013; 6: 1806-1816.

Ma Y, Chen L, Xie G, Zhou Y, Yue C, Yuan X, Zheng Y, Wang W, Deng L, Shen L: Elevated level of interleukin-35 in colorectal cancer induces conversion of T cells into iTr35 by activating STAT1/STAT3. Oncotarget 2016; 7: 73003-73015.

Li XQ, Yang XL, Zhang G, Wu SP, Deng XB, Xiao SJ, Liu QZ, Yao KT, Xiao GH: Nuclear beta-catenin accumulation is associated with increased expression of Nanog protein and predicts poor prognosis non-small cell lung cancer. J Transl Med 2013; 11: 114.

Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.

Article / Publication Details

Received: June 13, 2018
Accepted: November 23, 2018
Published online: November 30, 2018
Issue release date: December 2018

Number of Print Pages: 13
Number of Figures: 6
Number of Tables: 3

ISSN: 1015-8987 (Print)
eISSN: 1421-9778 (Online)

For additional information: https://www.karger.com/CPB

Figures

Tables

Open Access License / Drug Dosage / Disclaimer

This article is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND). Usage and distribution for commercial purposes as well as any distribution of modified material requires written permission. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

[1] Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, Stein KD, Alteri R, Jemal A: Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin 2016; 66: 271-289.

[2] Siegel RL, Miller KD, Jemal A: Cancer statistics, 2016. CA Cancer J Clin 2016; 66: 7-30.

[3] Torre LA, Sauer AM, Chen MS, Jr., Kagawa-Singer M, Jemal A, Siegel RL: Cancer statistics for Asian Americans, Native Hawaiians, and Pacific Islanders, 2016: Converging incidence in males and females. Cancer J Clin 2016; 66: 182-202.

[4] Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.

[5] Dougan M, Li D, Neuberg D, Mihm M, Googe P, Wong KK, Dranoff G: A dual role for the immune response in a mouse model of inflammation-associated lung cancer. J Clin Invest 2011; 121: 2436-2446.

[6] Zhong Z, Sanchez-Lopez E, Karin M: Autophagy, Inflammation, and Immunity: A Troika Governing Cancer and Its Treatment. Cell 2016; 166: 288-298.

[7] Collison LW, Workman CJ, Kuo TT, Boyd K, Wang Y, Vignali KM, Cross R, Sehy D, Blumberg RS, Vignali DA: The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 2007; 450: 566-569.

[8] Chaturvedi V, Collison LW, Guy CS, Workman CJ, Vignali DA: Cutting edge: Human regulatory T cells require IL-35 to mediate suppression and infectious tolerance. J Immunol 2011; 186: 6661-6666.

[9] Nishino R, Takano A, Oshita H, Ishikawa N, Akiyama H, Ito H, Nakayama H, Miyagi Y, Tsuchiya E, Kohno N, Nakamura Y, Daigo Y: Identification of Epstein-Barr virus-induced gene 3 as a novel serum and tissue biomarker and a therapeutic target for lung cancer. Clin Cancer Res 2011; 17: 6272-6286.

[10] Nicholl MB, Ledgewood CL, Chen X, Bai Q, Qin C, Cook KM, Herrick EJ, Diaz-Arias A, Moore BJ, Fang Y: IL-35 promotes pancreas cancer growth through enhancement of proliferation and inhibition of apoptosis: evidence for a role as an autocrine growth factor. Cytokine 2014; 70: 126-133.

[11] Zhang Y, Sun H, Wu H, Tan Q, Xiang K: Interleukin 35 is an independent prognostic factor and a therapeutic target for nasopharyngeal carcinoma. Contemp Oncol (Pozn) 2015; 19: 120-124.

[12] Fan YG, Zhai JM, Wang W, Feng B, Yao GL, An YH, Zeng C: IL-35 over-expression is associated with genesis of gastric cancer. Asian Pac J Cancer Prev 2015; 16: 2845-2849.

[13] Fu YP, Yi Y, Cai XY, Sun J, Ni XC, He HW, Wang JX, Lu ZF, Huang JL, Cao Y, Zhou J, Fan J, Qiu SJ: Overexpression of interleukin-35 associates with hepatocellular carcinoma aggressiveness and recurrence after curative resection. Br J Cancer 2016; 114: 767-776.

[14] Long J, Guo H, Cui S, Zhang H, Liu X, Li D, Han Z, Xi L, Kou W, Xu J, Li TS, Ding Y: IL-35 expression in hepatocellular carcinoma cells is associated with tumor progression. Oncotarget 2016; 7: 45678-45686.

[15] Qiu X, Wang X, Song Y, Chen L: Plasma Level of Interleukin-35 as an Independent Prognostic Indicator in Hepatocellular Carcinoma. Dig Dis Sci 2016; 61: 3513-3521.

[16] Chen G, Liang Y, Guan X, Chen H, Liu Q, Lin B, Chen C, Huang M, Chen J, Wu W, Liang Y, Zhou K, Zeng J: Circulating low IL-23: IL-35 cytokine ratio promotes progression associated with poor prognosisin breast cancer. Am J Transl Res 2016; 8: 2255-2264.

[17] Zhao Z, Chen X, Hao S, Jia R, Wang N, Chen S, Li M, Wang C, Mao H: Increased interleukin-35 expression in tumor-infiltrating lymphocytes correlates with poor prognosis in patients with breast cancer. Cytokine 2017; 89: 76-81.

[18] Jin L, Xu X, Ye B, Pan M, Shi Z, Hu Y: Elevated serum interleukin-35 levels correlate with poor prognosis in patients with clear cell renal cell carcinoma. Int J Clin Exp Med 2015; 8: 18861-18866.

[19] Zeng JC, Zhang Z, Li TY, Liang YF, Wang HM, Bao JJ, Zhang JA, Wang WD, Xiang WY, Kong B, Wang ZY, Wu BH, Chen XD, He L, Zhang S, Wang CY, Xu JF: Assessing the role of IL-35 in colorectal cancer progression and prognosis. Int J Clin Exp Pathol 2013; 6: 1806-1816.

[20] Ma Y, Chen L, Xie G, Zhou Y, Yue C, Yuan X, Zheng Y, Wang W, Deng L, Shen L: Elevated level of interleukin-35 in colorectal cancer induces conversion of T cells into iTr35 by activating STAT1/STAT3. Oncotarget 2016; 7: 73003-73015.

[21] Li XQ, Yang XL, Zhang G, Wu SP, Deng XB, Xiao SJ, Liu QZ, Yao KT, Xiao GH: Nuclear beta-catenin accumulation is associated with increased expression of Nanog protein and predicts poor prognosis non-small cell lung cancer. J Transl Med 2013; 11: 114.

[22] Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.

Cellular Physiology and Biochemistry

Retracted Paper

Interleukin-35 Expression in Non-Small Cell Lung Cancer is Associated with Tumor Progression

Related Articles for ""

Related Articles:

References

Article / Publication Details

Open Access License / Drug Dosage / Disclaimer

SOCIAL MEDIA

SOCIAL MEDIA

ABOUT US

SERVICES

RESOURCES